Tobias Maurer

Dec 30, 2024 | mdpi.com | Tobias Maurer

Article Menu /ajax/scifeed/subscribe Altmetric announcement Help format_quote Cite thumb_up ... Endorse Need Help? Find support for a specific problem in the support section of our website. Please let us know what you think of our products and services. Visit our dedicated information section to learn more about MDPI.

Mar 1, 2024 | jnm.snmjournals.org | Tobias Maurer |Christian Thomas |Boris A. Hadaschik |Molecular Imaging

The DETECT trial presented by Schilham et al. in The Journal of Nuclear Medicine constitutes one of the first prospective trials on prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) in primary prostate cancer patients (1).

Feb 15, 2024 | jnm.snmjournals.org | Tobias Maurer |Christian Thomas |Boris A. Hadaschik |Molecular Imaging

The DETECT trial presented by Schilham et al. in The Journal of Nuclear Medicine constitutes one of the first prospective trials on prostate-specific membrane antigen (PSMA) radioguided surgery (RGS) in primary prostate cancer patients (1).

Jul 5, 2023 | europeanurology.com | Matthias Eiber |Tobias Maurer |Mark Preston |Brian Helfand

AbstractRadiohybrid (rh) 18F-rhPSMA-7.3 is a novel high-affinity prostate-specific membrane antigen (PSMA)-targeting radiopharmaceutical for prostate cancer (PCa) imaging. To evaluate the diagnostic performance and safety of 18F-rhPSMA-7.3 in newly diagnosed PCa patients planned for prostatectomy. Data on 18F-rhPSMA-7.3 were reported from the phase 3 prospective, multicentre LIGHTHOUSE study (NCT04186819).